Triochem Products Ltd

AGM outcomes

• 54th AGM held on 22 August 2026 at 3:00 PM.
• Annual Report 2025-26 approved and adopted by members.
• Audited financial statements for FY2025-26 approved.
• Re-appointment of Shyam Sundar Sharma as Director, liable to retire by rotation.
• Continuation of Shyam Sundar Sharma as Non-Executive Non-Independent Director via Special Resolution (Reg 17(1A)).
• Remuneration for Sharma in re-appointment: Nil.
• Sharma aged 79; background: B.Com, LLB, FCA.
• Sharma attended 5/5 board meetings.

AGM details

• AGM held Aug 22, 2026 at 3:00 pm, physical in Mumbai; book closure Aug 14, 2026 (55 shareholders).

Key resolutions

• Adoption of Audited Financial Statements for year ended Mar 31, 2026; approved 100%.
• Re-appointment of Mr. Shyam Sundar Sharma as director liable to retire by rotation; approved 100%.
• Continuation of Mr. Sharma as Non-Executive, Non-Independent Director; approved 100%.

Director changes

• Shyam Sundar Sharma re-appointed; continues as Non-Executive, Non-Independent Director.

AGM Details

• Date: 22 August 2026; Time: 3:00 PM.
• Mode: physical with remote e-voting.
• Venue: registered office, Mumbai.
• Record date: 14 August 2026.
• Meeting concluded at 3:35 PM.

Resolutions & Voting

• Ordinary: Adopt Audited Financial Statements for year ended 31 March 2026.
• Ordinary: Re-appointment of Shyam Sundar Sharma (retiring by rotation).
• Special: Continuation of Shyam Sundar Sharma as Non-Executive, Non-Independent Director.
• Voting results to be announced/uploaded on company and exchange websites.

Dividend

• Dividend: No dividend proposed for 2025-26.

Directors & Continuation

• Shyam Sundar Sharma (79) seeks continuation as Non-Executive, Non-Independent.
• Continuation subject to special resolution under Item No. 3.

Auditors

• Auditors: No changes announced; existing statutory and secretarial auditors present.

Material Related Party Transactions

• Material RPT: Sale of immovable properties and investments approved via postal ballot in Dec 2025.
• RPT values: WDV of assets Rs 56.92 lakhs.
• FMV of assets approx Rs 672.05 lakhs; investments Rs 501.15 lakhs.
• Gain recognized: Rs 1116.65 lakhs.
• Sale completed in Jan–Feb 2026; proceeds for new ventures.

Other Approvals

• No ESOPs, borrowings, or charter amendments reported.

Applicability and status

• Mode of fund raising: Not applicable.
• Date of raising funds: Not applicable.
• Amount raised: Not applicable.
• Monitoring agency: Not applicable.
• Deviation/variation in use of funds: Not applicable.
• Shareholder approval: Not applicable.
• Audit Committee comments: Not applicable.
• Auditors' comments: Not applicable.

Key quarterly figures

• Total income from operations: Rs 16.56 lakhs in Q1 2026-27.
• PAT after tax: Rs 9.48 lakhs in Q1 2026-27.
• EPS (basic and diluted): Rs 3.87 in Q1 2026-27.
• Total comprehensive income: Rs 105.02 lakhs; OCI 95.54.
• Equity share capital: Rs 24.50 lakhs at 30-Jun-2026.
• Auditors: Kanu Doshi Associates LLP; unqualified conclusion.
• Board approved unaudited results on 14 Aug 2026.
• Single segment: chemical and pharmaceuticals; segment reporting not applicable.
• Prior period included Rs 1,116.65 lakhs exceptional gain on asset sale.

Financial results and compliance

• Unaudited standalone quarterly results for the quarter ended 30 June 2026 approved.
• Audit Committee reviewed results; Board approved in compliance with SEBI LODR Reg 33.
• Independent auditor Kanu Doshi Associates LLP issued an unqualified conclusion on the review.
• Limited Review Report noted; no material misstatement observed.
• Reg 32(1) deviation statement for Q1 2026: no issues.
• The Board noted compliance with securities laws; liquidity position described as comfortable.

Board meeting details

• No meeting date, time, venue, or agenda disclosed in this filing chunk.